These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 24848018)

  • 1. Oligonucleotide-based strategies to combat polyglutamine diseases.
    Fiszer A; Krzyzosiak WJ
    Nucleic Acids Res; 2014 Jun; 42(11):6787-810. PubMed ID: 24848018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases.
    Fiszer A; Olejniczak M; Switonski PM; Wroblewska JP; Wisniewska-Kruk J; Mykowska A; Krzyzosiak WJ
    BMC Mol Biol; 2012 Mar; 13():6. PubMed ID: 22397573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisense oligonucleotide therapeutics in neurodegenerative diseases: the case of polyglutamine disorders.
    Silva AC; Lobo DD; Martins IM; Lopes SM; Henriques C; Duarte SP; Dodart JC; Nobre RJ; Pereira de Almeida L
    Brain; 2020 Feb; 143(2):407-429. PubMed ID: 31738395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon.
    Evers MM; Tran HD; Zalachoras I; Pepers BA; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
    Neurobiol Dis; 2013 Oct; 58():49-56. PubMed ID: 23659897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silencing of genes responsible for polyQ diseases using chemically modified single-stranded siRNAs.
    Fiszer A; Ellison-Klimontowicz ME; Krzyzosiak WJ
    Acta Biochim Pol; 2016; 63(4):759-764. PubMed ID: 27770571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical Nanomedicines for Polyglutamine-Based Neurodegenerative Diseases.
    Lee LKC; Leong LI; Liu Y; Luo M; Chan HYE; Choi CHJ
    Mol Pharm; 2021 Feb; 18(2):610-626. PubMed ID: 32584043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The Role of Mutant RNA in the Pathogenesis of Huntington's Disease and Other Polyglutamine Diseases].
    Bogomazova AN; Eremeev AV; Pozmogova GE; Lagarkova MA
    Mol Biol (Mosk); 2019; 53(6):954-967. PubMed ID: 31876275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genes and pathways affected by CAG-repeat RNA-based toxicity in Drosophila.
    Shieh SY; Bonini NM
    Hum Mol Genet; 2011 Dec; 20(24):4810-21. PubMed ID: 21933837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Artificial miRNAs targeting CAG repeat expansion in ORFs cause rapid deadenylation and translation inhibition of mutant transcripts.
    Ciesiolka A; Stroynowska-Czerwinska A; Joachimiak P; Ciolak A; Kozlowska E; Michalak M; Dabrowska M; Olejniczak M; Raczynska KD; Zielinska D; Wozna-Wysocka M; Krzyzosiak WJ; Fiszer A
    Cell Mol Life Sci; 2021 Feb; 78(4):1577-1596. PubMed ID: 32696070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies.
    Bauer PO; Nukina N
    J Neurochem; 2009 Sep; 110(6):1737-65. PubMed ID: 19650870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polyglutamine Ataxias: Our Current Molecular Understanding and What the Future Holds for Antisense Therapies.
    McIntosh CS; Li D; Wilton SD; Aung-Htut MT
    Biomedicines; 2021 Oct; 9(11):. PubMed ID: 34829728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allele-selective suppression of mutant genes in polyglutamine diseases.
    Liu CR; Cheng TH
    J Neurogenet; 2015; 29(2-3):41-9. PubMed ID: 26174158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of RNA-induced toxicity in CAG repeat disorders.
    Nalavade R; Griesche N; Ryan DP; Hildebrand S; Krauss S
    Cell Death Dis; 2013 Aug; 4(8):e752. PubMed ID: 23907466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RNA toxicity induced by expanded CAG repeats in Huntington's disease.
    Martí E
    Brain Pathol; 2016 Nov; 26(6):779-786. PubMed ID: 27529325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat.
    Gagnon KT; Pendergraff HM; Deleavey GF; Swayze EE; Potier P; Randolph J; Roesch EB; Chattopadhyaya J; Damha MJ; Bennett CF; Montaillier C; Lemaitre M; Corey DR
    Biochemistry; 2010 Nov; 49(47):10166-78. PubMed ID: 21028906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Huntingtin aggregation and toxicity in Huntington's disease.
    Bates G
    Lancet; 2003 May; 361(9369):1642-4. PubMed ID: 12747895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing a peptidylic inhibitor-based therapeutic approach that simultaneously suppresses polyglutamine RNA- and protein-mediated toxicities in patient cells and Drosophila.
    Zhang Q; Tsoi H; Peng S; Li PP; Lau KF; Rudnicki DD; Ngo JC; Chan HY
    Dis Model Mech; 2016 Mar; 9(3):321-34. PubMed ID: 26839389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant CAG Repeats Effectively Targeted by RNA Interference in SCA7 Cells.
    Fiszer A; Wroblewska JP; Nowak BM; Krzyzosiak WJ
    Genes (Basel); 2016 Dec; 7(12):. PubMed ID: 27999335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNAi: a potential therapy for the dominantly inherited nucleotide repeat diseases.
    Denovan-Wright EM; Davidson BL
    Gene Ther; 2006 Mar; 13(6):525-31. PubMed ID: 16237462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oligonucleotide therapeutic approaches for Huntington disease.
    Sah DW; Aronin N
    J Clin Invest; 2011 Feb; 121(2):500-7. PubMed ID: 21285523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.